November 6th, 2026Empire Forum 2026: Ambati on K8 phase 2 results in geographic atrophyJayakrishna Ambati, MD, discusses phase 2 K8 results in GA, its inflammasome mechanism, and dosing designed for convenience.Read more
November 20th, 2026Why ST-100 is expanding from dry eye into corneal wound healingEric Schlumpf discusses why Stuart Therapeutics is taking vezocolmitide beyond dry eye disease and into corneal wound healing.Read more
November 20th, 2026ONL Therapeutics completes enrollment in Phase 2 GALAXY trial for geographic atrophyA first-in-class small-molecule Fas inhibitor delivered by intravitreal injection is now under evaluation in more than 324 patients across North America and Europe.Read more
November 19th, 2026Eichenbaum Acorns: Building the private academic model with Jeffrey S. Heier, MDFor Jeffrey S. Heier, MD, shaping retina trials, joining industry, and staying in clinic all rest on family and a strong team.Read more
November 18th, 2026The One Thing: Retinopathy’s slow slide, undetected blindness, innovation for all | Episode 7Patricio G. Schlottmann, MD, Nicholas J. Volpe, MD, and Hunter Cherwek, MD, point to retinopathy follow-up, missed diagnoses, and low-resource care.Read more
November 14th, 2026How Lambert-Eaton myasthenic syndrome presents around the eyesAlfredo A. Sadun, MD, PhD, explains how LEMS mimics myasthenia gravis around the eyes and why its cancer link matters.Read more
November 13th, 2026OT Roundup: GLP-1 NAION warning, LEMS clues, Eyedaptic Eva, AFibThe FDA adds a NAION warning to GLP-1 drugs, plus LEMS clues, Eyedaptic's new Eva AI assistant and a retinal imaging link to AFib.Read more
November 12th, 2026Inflammasome inhibition with K8 in geographic atrophy: A Q&AJayakrishna Ambati, MD, discusses phase 2 K8 findings in geographic atrophy, inflammasome targeting and K8 dosing and delivery.Read more